Advertisement

Is Alkylating Agent “Priming” a DNA Repair Phenomenon?

  • J. L. Millar
  • B. C. Millar
  • M. Tilby
  • B. D. Evans
Part of the Developments in Oncology book series (DION, volume 23)

Abstract

In the late sixties Jeney, Connors and Jones (1) showed that a low dose of merophan could reduce the toxicity of a second high dose of the same drug or melphalan. Similar protection against radiation-induced death was also demonstrated when mice were pretreated with colchicine or vinca alkaloids (2). In 1975 Millar and coworkers showed that the recovery of bone marrow CFUs, in mice receiving a small dose of cyclophosphamide 2 days before a high dose of busulphan, was enhanced (3). The same group has since shown that the enhanced recovery of normal tissue is not accompanied by a protective effect towards the tumour (4,5). This phenomenon has been called “priming” and has been demonstrated using a range of drugs including cytosine arabinoside (AraC) as the “priming” (i.e. small dose) agent. Notable exceptions are radiation and busulphan (6).

Keywords

Vinca Alkaloid Challenge Dose Chinese Hamster Cell Late Sixty Human Bone Marrow Cell 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Jeney A jr, Connors TA, Jones M: The toxicity of merophan after treatment with subtoxic dose. Acta Physiol Acad Scien Hung Tomus (33): 89–94, 1968.Google Scholar
  2. 2.
    Smith WW, Wilson SM: Effects of vinblastine and vincristine on survival and haemopoiesis in irradiated mice. J Nat Can Inst (39): 1055–1066, 1967.Google Scholar
  3. 3.
    Millar JL, Hudspith BN, Blackett: Reduced lethality in mice receiving a combined dose of cyclophosphamide and busulphan. Br J Cancer (32): 193–198, 1975.PubMedCrossRefGoogle Scholar
  4. 4.
    Millar JL, McElwain TJ: Combinations of cytotoxic agents that have much less than expected toxicity on normal tissues in mice. Antibiotics Chemother (23): 271–282, 1978.Google Scholar
  5. 5.
    Millar JL, Stephens TC, Wist EA: An explanation for the ability of cytotoxic drug pretreatment to reduce bone marrow related lethality of total body irradiation (TBI). Inc J Radiation Oncology Biol Phys (8): 581–583, 1982.CrossRefGoogle Scholar
  6. 6.
    Millar JL, Blackett NM, Hudspith BN: Enhanced post-irradiation recovery of the haemopoietic system in animals pretreated with a variety of cytotoxic agents. Cell Tissue Kinet (II): 543–553, 1973.Google Scholar
  7. 7.
    Millar BC, Jinks S: The effect of dexamethasone on the radiation survival response and misonidazole induced hypoxic-cell toxicity in Chinese Hamster cells V-79-753B in vitro. Br J Radiol (54): 505–511, 1981.PubMedCrossRefGoogle Scholar
  8. 8.
    Millar JL, McElwain TJ, Clutterbuck RD, Wist EA: The modification of melphalan toxicity in tumour bearing mice by S-2-(3-aminoprophylamino)-cyclophorothioic acid (WR 2721). Am J Clin Oncol (5): 321–328, 1982.PubMedCrossRefGoogle Scholar
  9. 9.
    Evans BD, Smith IE, Clutterbuck RD, Millar JL: Prevention of acute deaths in mice after very high dose cyclophosphamide by a divided dose schedule. Br J Cancer (48):(In press).Google Scholar
  10. 10.
    Millar JL, Hudspith BN, McElwain TJ, Phelps TA: Effects of high-dose melphalan on marrow and intestinal epithelium in mice pretreated with cyclophosphamide. Br J Cancer (38): 137–142, 1978.PubMedCrossRefGoogle Scholar
  11. 11.
    Burke PJ, Diggs CH, Owens AH jr: Factors in human serum affecting the proliferation of normal and leukaemic cells Cancer Res (33): 800–806, 1973.PubMedGoogle Scholar

Copyright information

© Martinus Nijhoff Publishing, Boston 1984

Authors and Affiliations

  • J. L. Millar
  • B. C. Millar
  • M. Tilby
  • B. D. Evans

There are no affiliations available

Personalised recommendations